Compare WS & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | HRMY |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2023 | 2020 |
| Metric | WS | HRMY |
|---|---|---|
| Price | $38.20 | $32.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $42.50 | ★ $44.11 |
| AVG Volume (30 Days) | 198.0K | ★ 799.5K |
| Earning Date | 03-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | 1.30 | ★ 2.71 |
| Revenue | ★ $3,093,300,000.00 | $868,453,000.00 |
| Revenue This Year | $16.77 | $19.75 |
| Revenue Next Year | $2.69 | $12.88 |
| P/E Ratio | $29.95 | ★ $11.72 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $24.36 | $25.52 |
| 52 Week High | $49.17 | $40.87 |
| Indicator | WS | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.43 | 66.25 |
| Support Level | $38.01 | $32.13 |
| Resistance Level | $39.29 | $33.21 |
| Average True Range (ATR) | 1.51 | 1.32 |
| MACD | 0.49 | 0.19 |
| Stochastic Oscillator | 76.47 | 58.88 |
Worthington Steel Inc is a processor of carbon flat-rolled steel, a producer of laser-welded solutions, and a provider of electrical steel laminations. The company has manufacturing facilities across the United States, Canada, China, India, Germany and Mexico. It buys coils of steel from primary steel producers and processes them to precise type, thickness, length, width, shape, and surface quality required by customer specifications. The company's product lines and processing capabilities include; carbon flat-rolled steel processing, electrical steel laminations, and tailor welded products. Geographically, the company generates a majority of its revenue from the United States followed by Canada, Mexico, and other regions.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.